A mutation threshold distinguishes the antitumorigenic effects of the mitochondrial gene MTND1, an Oncojanus function

Cancer Research

Volumn 71, Issue 19, 2011, Pages 6220-6229

  Gasparre, Giuseppe ^a   Kurelac, Ivana ^a   Capristo, Mariantonietta ^a   Iommarini, Luisa ^a   Ghelli, Anna ^a   Ceccarelli, Claudio ^b   Nicoletti, Giordano ^c   Nanni, Patrizia ^a   De Giovanni, Carla ^a   Scotlandi, Katia ^c   Betts, Christine M ^a   Carelli, Valerio ^a   Lollini, Pier Luigi ^a   Romeo, Giovanni ^a   Rugolo, Michela ^a   Porcelli, Anna Maria ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXOGLUTARIC ACID; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOCHONDRIAL DNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SUCCINIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER INVASION; CONTROLLED STUDY; DOWN REGULATION; GENE CONTROL; GENE INSERTION; GENE MUTATION; HETEROPLASMY; HOMOPLASMY; HUMAN; HUMAN CELL; INHERITANCE; MALIGNANT TRANSFORMATION; METASTASIS POTENTIAL; MITOCHONDRIAL GENE; MOUSE; MTND1 GENE; NONHUMAN; ONCOJANUS GENE; PRIORITY JOURNAL; PROTEIN STABILITY; TUMOR CELL CULTURE; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; ELECTRON TRANSPORT COMPLEX I; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MITOCHONDRIAL; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KETOGLUTARIC ACIDS; MICE; MICE, INBRED BALB C; MICE, NUDE; MUTATION; NADH DEHYDROGENASE; NEOPLASMS, EXPERIMENTAL; SUCCINIC ACID;

EID: 80053362687     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-1042     Document Type: Article

References (39)

1. Ishikawa K, Takenaga K, Akimoto M, Koshikawa N, Yamaguchi A, Imanishi H, et al. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 2008;320:661-4. (Pubitemid 351928347)
2. Shidara Y, Yamagata K, Kanamori T, Nakano K, Kwong JQ, Manfredi G, et al. Positive contribution of pathogenic mutations in the mitochondrial genome to the promotion of cancer by prevention from apoptosis. Cancer Res 2005;65:1655-63. (Pubitemid 40478589)
3. Park JS, Sharma LK, Li H, Xiang R, Holstein D, Wu J, et al. A heteroplasmic, not homoplasmic, mitochondrial DNA mutation promotes tumorigenesis via alteration in reactive oxygen species generation and apoptosis. Hum Mol Genet 2009;18:1578-89.
4. Petros JA, Baumann AK, Ruiz-Pesini E, Amin MB, Sun CQ, Hall J, et al. mtDNA mutations increase tumorigenicity in prostate cancer. Proc Natl Acad Sci U S A 2005;102:719-24. (Pubitemid 40282732)
5. Thompson CB. Metabolic enzymes as oncogenes or tumor suppressors. N Engl J Med 2009;360:813-5.
6. Gottlieb E, Tomlinson IP. Mitochondrial tumour suppressors: a genetic and biochemical update. Nat Rev Cancer 2005;5:857-66. (Pubitemid 41746030)
7. Pollard PJ, Briere JJ, Alam NA, Barwell J, Barclay E, Wortham NC, et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 2005;14:2231-9. (Pubitemid 41418022)
8. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005; 7:77-85. (Pubitemid 40126384)
9. Chen Z, Lu W, Garcia-Prieto C, Huang P. The Warburg effect and its cancer therapeutic implications. J Bioenerg Biomembr 2007;39: 267-74. (Pubitemid 47619379)
10. Smolkova K, Plecita-Hlavata L, Bellance N, Benard G, Rossignol R, Jezek P. Waves of gene regulation suppress and then restore oxidative phosphorylation in cancer cells. Int J Biochem Cell Biol 2011; 43:950-68.
11. Costa-Guda J, Tokura T, Roth SI, Arnold A. Mitochondrial DNA mutations in oxyphilic and chief cell parathyroid adenomas. BMC Endocr Disord 2007;7:8.
12. Gasparre G, Hervouet E, de LE, Demont J, Pennisi LF, Colombel M, et al. Clonal expansion of mutated mitochondrial DNA is associated with tumor formation and complex I deficiency in the benign renal oncocytoma. Hum Mol Genet 2008;17:986-95. (Pubitemid 351426033)
13. Gasparre G, Iommarini L, Porcelli AM, Lang M, Ferri GG, Kurelac I, et al. An inherited mitochondrial DNA disruptive mutation shifts to homoplasmy in oncocytic tumor cells. Hum Mutat 2009;30: 391-6.
14. Gasparre G, Porcelli AM, Bonora E, Pennisi LF, Toller M, Iommarini L, et al. Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors. Proc Natl Acad Sci U S A 2007;104:9001-6. (Pubitemid 47175426)
15. Mayr JA, Meierhofer D, Zimmermann F, Feichtinger R, Kogler C, Ratschek M, et al. Loss of complex I due to mitochondrial DNA mutations in renal oncocytoma. Clin Cancer Res 2008;14:2270-5. (Pubitemid 351551057)
16. Maximo V, Soares P, Lima J, Cameselle-Teijeiro J, Sobrinho-Simoes M. Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hurthle cell tumors. Am J Pathol 2002;160:1857-65. (Pubitemid 34525665)
17. Habano W, Sugai T, Yoshida T, Nakamura S. Mitochondrial gene mutation, but not large-scale deletion, is a feature of colorectal carcinomas with mitochondrial microsatellite instability. Int J Cancer 1999;83:625-9. (Pubitemid 29508041)
18. Jeronimo C, Nomoto S, Caballero OL, Usadel H, Henrique R, Varzim G, et al. Mitochondrial mutations in early stage prostate cancer and bodily fluids. Oncogene 2001;20:5195-8. (Pubitemid 32844048)
19. Polyak K, Li Y, Zhu H, Lengauer C, Willson JK, Markowitz SD, et al. Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat Genet 1998;20:291-3. (Pubitemid 28507677)
20. Bonora E, Porcelli AM, Gasparre G, Biondi A, Ghelli A, Carelli V, et al. Defective oxidative phosphorylation in thyroid oncocytic carcinoma is associated with pathogenic mitochondrial DNA mutations affecting complexes I and III. Cancer Res 2006;66:6087-96.
21. Gasparre G, Bonora E, Tallini G, Romeo G. Molecular features of thyroid oncocytic tumors. Mol Cell Endocrinol 2010;321:67-76.
22. Gasparre G, Romeo G, Rugolo M, Porcelli AM. Learning from oncocytic tumors: why choose inefficient mitochondria? Biochim Biophys Acta 2011;1807:633-42.
23. Porcelli AM, Ghelli A, Ceccarelli C, Lang M, Cenacchi G, Capristo M, et al. The genetic and metabolic signature of oncocytic transformation implicates HIF1alpha destabilization. Hum Mol Genet 2010;19: 1019-32.
24. Zielke A, Tezelman S, Jossart GH, Wong M, Siperstein AE, Duh QY, et al. Establishment of a highly differentiated thyroid cancer cell line of Hurthle cell origin. Thyroid 1998;8:475-83. (Pubitemid 28311296)
25. Kurelac I, Lang M, Zuntini R, Calabrese C, Simone D, Vicario S, et al. Searching for a needle in the haystack: comparing six methods to evaluate heteroplasmy in difficult sequence context. Biotech Adv Jun 13. [Epub ahead of print].
26. Porcelli AM, Ghelli A, Iommarini L, Mariani E, Hoque M, Zanna C, et al. The antioxidant function of Bcl-2 preserves cytoskeletal stability of cells with defective respiratory complex I. Cell Mol Life Sci 2008;65:2943-51.
27. Porcelli AM, Angelin A, Ghelli A, Mariani E, Martinuzzi A, Carelli V, et al. Respiratory complex I dysfunction due to mitochondrial DNA mutations shifts the voltage threshold for opening of the permeability transition pore toward resting levels. J Biol Chem 2009;284:2045-52.
28. Ghelli A, Porcelli AM, Zanna C, Vidoni S, Mattioli S, Barbieri A, et al. The background of mitochondrial DNA haplogroup J increases the sensitivity of Leber's hereditary optic neuropathy cells to 2,5-hexanedione toxicity. PLoS One 2009;4:e7922.
29. Nanni P, Nicoletti G, Landuzzi L, Croci S, Murgo A, Palladini A, et al. High metastatic efficiency of human sarcoma cells in Rag2/gammac double knockout mice provides a powerful test system for antimetastatic targeted therapy. Eur J Cancer 2010;46:659-68.
30. Chen Y, Cairns R, Papandreou I, Koong A, Denko NC. Oxygen consumption can regulate the growth of tumors, a new perspective on the Warburg effect. PLoS One 2009;4:e7033.
31. Zimmermann FA, Mayr JA, Neureiter D, Feichtinger R, Alinger B, Jones ND, et al. Lack of complex I is associated with oncocytic thyroid tumours. Br J Cancer 2009;100:1434-7.
32. Maxwell PH, Pugh CW, Ratcliffe PJ. Activation of the HIF pathway in cancer. Curr Opin Genet Dev 2001;11:293-9. (Pubitemid 32480296)
33. Bruick RK. Oxygen sensing in the hypoxic response pathway: regulation of the hypoxia-inducible transcription factor. Genes Dev 2003;17:2614-23. (Pubitemid 37363065)
34. Tuppen HA, Hogan VE, He L, Blakely EL, Worgan L, Al-Dosary M, et al. The p.M292T NDUFS2 mutation causes complex I-deficient Leigh syndrome in multiple families. Brain 2010;133:2952-63.
35. Morán M, Rivera H, Sánchez-Aragó M, Blázquez A, Merinero B, Ugalde C, et al. Mitochondrial bioenergetics and dynamics interplay in complex I-deficient fibroblasts. Biochim Biophys Acta 2010; 1802:443-53.
36. Koopman WJ, Verkaart S, Visch HJ, van Emst-de Vries S, Nijtmans LG, Smeitink JA, et al. Human NADH:ubiquinone oxidoreductase deficiency: radical changes in mitochondrial morphology? Am J Physiol Cell Physiol 2007;293:C22-9. (Pubitemid 47105004)
37. Tallini G. Oncocytic tumours. Virchows Arch 1998;433:5-12. (Pubitemid 28356470)
38. MacKenzie ED, Selak MA, Tennant DA, Payne LJ, Crosby S, Frederiksen CM, et al. Cell-permeating alpha-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells. Mol Cell Biol 2007;27:3282-9. (Pubitemid 46685207)
39. Boulet L, Karpati G, Shoubridge EA. Distribution and threshold expression of the tRNA(Lys) mutation in skeletal muscle of patients with myoclonic epilepsy and ragged-red fibers (MERRF). Am J Hum Genet 1992;51:1187-200. (Pubitemid 23001078)